Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $1.2 billion.

  • UNITED THERAPEUTICS's Income towards Parent Company rose 9.58% to $338.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 14.47%. This contributed to the annual value of $1.2 billion for FY2024, which is 21.35% up from last year.
  • UNITED THERAPEUTICS's Income towards Parent Company amounted to $1.2 billion in FY2024, which was up 21.35% from $984.8 million recorded in FY2023.
  • UNITED THERAPEUTICS's 5-year Income towards Parent Company high stood at $1.2 billion for FY2024, and its period low was $475.8 million during FY2021.
  • In the last 3 years, UNITED THERAPEUTICS's Income towards Parent Company had a median value of $984.8 million in 2023 and averaged $969.1 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first spiked by 592.63% in 2020, then decreased by 7.58% in 2021.
  • UNITED THERAPEUTICS's Income towards Parent Company (Yearly) stood at $514.8 million in 2020, then dropped by 7.58% to $475.8 million in 2021, then surged by 52.86% to $727.3 million in 2022, then soared by 35.40% to $984.8 million in 2023, then increased by 21.35% to $1.2 billion in 2024.